Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.
Liontos M, Trigka EA, Korkolopoulou P, Tzannis K, Lainakis G, Koutsoukos K, Kostouros E, Lykka M, Papandreou CN, Karavasilis V, Christodoulou C, Papatsoris A, Skolarikos A, Varkarakis I, Adamakis I, Alamanis C, Stravodimos K, Mitropoulos D, Deliveliotis C, Constantinidis CA, Saetta A, Patsouris E, Dimopoulos MΑ, Bamias A. Liontos M, et al. Among authors: papandreou cn. World J Urol. 2017 Mar;35(3):411-419. doi: 10.1007/s00345-016-1890-7. Epub 2016 Jul 9. World J Urol. 2017. PMID: 27395374
Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.
Bamias A, Karadimou A, Lampaki S, Lainakis G, Malettou L, Timotheadou E, Papazisis K, Andreadis C, Kontovinis L, Anastasiou I, Stravodimos K, Xanthakis I, Skolarikos A, Christodoulou C, Syrigos K, Papandreou C, Razi E, Dafni U, Fountzilas G, Dimopoulos MA. Bamias A, et al. BMC Cancer. 2010 Feb 18;10:45. doi: 10.1186/1471-2407-10-45. BMC Cancer. 2010. PMID: 20163744 Free PMC article.
Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma.
Papazisis KT, Kontovinis LF, Papandreou CN, Kouvatseas G, Lafaras C, Antonakis E, Christopoulou M, Andreadis C, Mouratidou D, Kortsaris AH. Papazisis KT, et al. Among authors: papandreou cn. BMC Cancer. 2010 Sep 14;10:489. doi: 10.1186/1471-2407-10-489. BMC Cancer. 2010. PMID: 20840755 Free PMC article.
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.
Fountzilas G, Kourea HP, Bobos M, Televantou D, Kotoula V, Papadimitriou C, Papazisis KT, Timotheadou E, Efstratiou I, Koutras A, Pentheroudakis G, Christodoulou C, Aravantinos G, Miliaras D, Petraki K, Papandreou CN, Papakostas P, Bafaloukos D, Repana D, Razis E, Pectasides D, Dimopoulos AM. Fountzilas G, et al. Among authors: papandreou cn. Anticancer Res. 2011 Sep;31(9):3007-18. Anticancer Res. 2011. PMID: 21868552
Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G, Kotoula V, Kouvatseas G, Charalambous E, Dionysopoulos D, Zagouri F, Koutras A, Papazisis K, Pectasides D, Samantas E, Dimopoulos MA, Papandreou CN, Fountzilas G. Pentheroudakis G, et al. Among authors: papandreou cn. Clin Breast Cancer. 2014 Oct;14(5):330-8. doi: 10.1016/j.clbc.2014.02.009. Epub 2014 Mar 1. Clin Breast Cancer. 2014. PMID: 24703319 Clinical Trial.
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.
Karavasilis V, Kosmidis P, Syrigos KN, Mavropoulou P, Dimopoulos MA, Kotoula V, Pectasides D, Boukovinas I, Klouvas G, Kalogera-Fountzila A, Papandreou CN, Fountzilas G, Briasoulis E. Karavasilis V, et al. Among authors: papandreou cn. Anticancer Res. 2014 Oct;34(10):5649-55. Anticancer Res. 2014. PMID: 25275069 Clinical Trial.
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G, Giannoulatou E, Alexopoulou Z, Zagouri F, Timotheadou E, Papadopoulou K, Lakis S, Bobos M, Poulios C, Sotiropoulou M, Lyberopoulou A, Gogas H, Pentheroudakis G, Pectasides D, Koutras A, Christodoulou C, Papandreou C, Samantas E, Papakostas P, Kosmidis P, Bafaloukos D, Karanikiotis C, Dimopoulos MA, Kotoula V. Fountzilas G, et al. Oncotarget. 2016 May 31;7(22):32731-53. doi: 10.18632/oncotarget.9022. Oncotarget. 2016. PMID: 27129168 Free PMC article.
Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Kotoula V, Karavasilis V, Zagouri F, Kouvatseas G, Giannoulatou E, Gogas H, Lakis S, Pentheroudakis G, Bobos M, Papadopoulou K, Tsolaki E, Pectasides D, Lazaridis G, Koutras A, Aravantinos G, Christodoulou C, Papakostas P, Markopoulos C, Zografos G, Papandreou C, Fountzilas G. Kotoula V, et al. Breast Cancer Res Treat. 2016 Jul;158(2):307-21. doi: 10.1007/s10549-016-3883-z. Epub 2016 Jul 1. Breast Cancer Res Treat. 2016. PMID: 27369359
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
Christodoulou C, Kalogera-Fountzila A, Karavasilis V, Kouvatseas G, Papandreou CN, Samantas E, Varaki K, Papadopoulos G, Bobos M, Rallis G, Razis E, Goudopoulou A, Kalogeras KT, Syrigos KN, Fountzilas G. Christodoulou C, et al. Among authors: papandreou cn. J Neurooncol. 2017 Sep;134(2):443-451. doi: 10.1007/s11060-017-2548-z. Epub 2017 Jul 7. J Neurooncol. 2017. PMID: 28687923 Clinical Trial.
125 results